Mikhail Blagosklonny teaches oncology at the Rowell Park Cancer Institute. A scientist by profession, he is well known for his extensive study on the subjects of cancer and Aging. His prowess in science is courtesy of his MD in internal medicine, earned from the first Pavlov State Medical University of St. Petersburg. He prides himself on having received a Ph.D. in Experimental Medicine and Cardiology from the same institution.In 2002, Mikhail became the associate medicine professor at the new york medical college in Valhalla, new york. Later on, he served as a senior scientist at the Ordway Research Institute. He then joined the Rosewell Park Institute in 2009, where he is the current professor of Oncology. His extensive experience made him a force to reckon with in the field of oncology. He mainly focuses his research on Biogerontology (the mechanisms of aging) cancer, anti-aging drugs, and targeted cancer therapies that guard the normal cell against damage.Mikhail Blagosklonny is the current editor in chief of the Oncotarget and Cell Cycle. On top of all the achievements mentioned above, he is also the associate editor of cancer therapy and biology.
He is a prominent member of the Cell Death and Differentiation editorial board. Indeed, his scientific knowledge in oncology is unrivaled by many, and this has seen him serve many organizations dedicated to curing cancer and finding a cure for aging.Mikhail’s contribution to the subject of aging is significant. He drafted a hypothesis that aimed at describing the potential role of TOR Signaling in cancer and aging. His theory is based on Rapamycin. Essentially, Rapamycin is a drug that has been popularly used to treat cancer. In his hypothesis, he suggests that Rapamycin and a few other clinical drugs can be used effectively to treat cancer and slow down the aging process in the human body. Although his hypothesis is still subject to review and further research, Mikhail has set the tone for scientific research on the topics of cancer treatment and combating aging. He strongly advocates for the use of Rapamycin to ensure that people live the longest life possible.
Although many people may primarily know Mikhail for his hypothesis, his research is quite diverse. His research subjects range from clinical investigations to cellular and molecular biology. Mikhail’s research mainly entails ontogenesis, signal transduction, tumor suppressors, apoptosis, drug resistance for normal cells selective protection, cell cycle mitosis, and anticancer therapy.In addition to his scientific research on traditional subjects such as aging and cancer, Mikhail has written critical articles on relevant topics such as chemotherapeutic engineering and cell cyclotherapy. He is also the author of the hyper function theory.Throughout his career, Mikhail has written over 300 research articles, reviews, and book chapters. His hard work and dedication are responsible for his prominence in oncology research today. He attributes his commitment to his work to his undying love for humanity and a vision for a disease free world.